Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy of Using Interleukin-2 in Antiretroviral Naïve HIV Patients (ANRS119)
- Conditions
- First Posted Date
- 2005-07-15
- Last Posted Date
- 2011-12-22
- Target Recruit Count
- 130
- Registration Number
- NCT00120185
- Locations
- 🇫🇷
Service des Maladies Infectieuses, Paris, France
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
- First Posted Date
- 2005-05-16
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 267
- Registration Number
- NCT00110812
- Locations
- 🇺🇸
NIH Clinical Ctr., NIAID HIV Clinic CRS, Bethesda, Maryland, United States
🇺🇸Providence Portland Med. Ctr., Ambulatory Care and Education Ctr. CRS, Portland, Oregon, United States
🇺🇸Washington DC VAMC, Washington Regional AIDS Program, Infectious Diseases CRS, Washington, District of Columbia, United States
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2023-08-22
- Target Recruit Count
- 43
- Registration Number
- NCT00101101
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
- Conditions
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2006-02-06
- Lead Sponsor
- Chiron Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT00100737
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer
- First Posted Date
- 2005-01-07
- Last Posted Date
- 2013-08-16
- Target Recruit Count
- 18
- Registration Number
- NCT00100906
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
- Conditions
- First Posted Date
- 2004-03-29
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00080353
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer
- First Posted Date
- 2003-10-28
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 69
- Registration Number
- NCT00003126
- Locations
- 🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Summit Medical Center, Oakland, California, United States
Therapeutic HIV Vaccine and Interleukin-2 to Increase the Immune System's Response to HIV
- Conditions
- First Posted Date
- 2003-03-25
- Last Posted Date
- 2016-12-14
- Target Recruit Count
- 92
- Registration Number
- NCT00056797
- Locations
- 🇺🇸
NY Presbyterian Weill Cornell Medical Center, New York, New York, United States
Studies of Influenza Vaccine and Tetanus-Pneumococcal Vaccine in HIV-infected Patients Receiving Interleukin-2
- Conditions
- First Posted Date
- 2002-12-18
- Last Posted Date
- 2013-11-21
- Target Recruit Count
- 620
- Registration Number
- NCT00050726
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇩🇰Hvidovre University Hospital@@@Copenhagen, Denmark, Copenhagen, Denmark
Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 141
- Registration Number
- NCT00001705
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.